We provide strong evidence that the designed synthetic 7aaRGD peptide, which targets SPP1/integrin-mediated signaling and has been previously validated in in vitro experiments [21], blocks tumor-induced reprogramming of myeloid cells in vivo. The gene discussed is SPP1; the disease is neoplasm.